There shall be no administrative or judicial review of any of the following:
(1)
The determination of a unit, with respect to a drug or biological product, pursuant to section 1320f(c)(6) of this title.
(2)
The selection of drugs under section 1320f–1(b) of this title, the determination of negotiation-eligible drugs under section 1320f–1(d) of this title, and [1] the determination of qualifying single source drugs under section 1320f–1(e) of this title the [2] application of section 1320f–1(f) of this title,.[3]
(3)
The determination of a maximum fair price under subsection (b) or (f) of section 1320f–3 of this title.
(4)
The determination of renegotiation-eligible drugs under section 1320f–3(f)(2) of this title and the selection of renegotiation-eligible drugs under section 1320f–3(f)(3) of this title.
(Aug. 14, 1935, ch. 531, title XI, § 1198, as added and amended Pub. L. 117–169, title I, §§ 11001(a), 11002(a)(5), Aug. 16, 2022, 136 Stat. 1851, 1861.)